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Background: Despite recent advances in acute stroke treatment, basilar artery occlusion (BAO) is associated with a
death or disability rate of close to 70%. Randomised trials have shown the safety and efficacy of intravenous
thrombolysis (IVT) given within 4.5 h and have shown promising results of intra-arterial thrombolysis given within 6
h of symptom onset of acute ischaemic stroke, but these results do not directly apply to patients with an acute
BAO because only few, if any, of these patients were included in randomised acute stroke trials.
Recently the results of the Basilar Artery International Cooperation Study (BASICS), a prospective registry of patients
with acute symptomatic BAO challenged the often-held assumption that intra-arterial treatment (IAT) is superior to
IVT. Our observations in the BASICS registry underscore that we continue to lack a proven treatment modality for
patients with an acute BAO and that current clinical practice varies widely.
Design: BASICS is a randomised controlled, multicentre, open label, phase III intervention trial with blinded
outcome assessment, investigating the efficacy and safety of additional IAT after IVT in patients with BAO. The trial
targets to include 750 patients, aged 18 to 85 years, with CT angiography or MR angiography confirmed BAO
treated with IVT. Patients will be randomised between additional IAT followed by optimal medical care versus
optimal medical care alone. IVT has to be initiated within 4.5 h from estimated time of BAO and IAT within 6 h. The
primary outcome parameter will be favourable outcome at day 90 defined as a modified Rankin Scale score of 0–3.
Discussion: The BASICS registry was observational and has all the limitations of a non-randomised study. As the IAT
approach becomes increasingly available and frequently utilised an adequately powered randomised controlled
phase III trial investigating the added value of this therapy in patients with an acute symptomatic BAO is needed
(clinicaltrials.gov: NCT01717755).
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Stroke is the leading cause of disability in developed
countries [1]. Posterior circulation stroke accounts for
about 20% of all ischaemic strokes. The basilar artery is
the main vessel of the posterior circulation that supplies
most of the brainstem and occipital lobes, and part of
the cerebellum and thalami. Basilar artery occlusion
(BAO) can cause many symptoms such as isolated cra-
nial nerve palsies or hemiplegia, but also a locked-in
state or coma. Despite recent advances in acute stroke
treatment BAO is associated with death or disability rate
of close to 70% [2].
Randomised trials have shown the safety and efficacy
of intravenous thrombolysis given within 4.5 h and
promising results of intra-arterial thrombolysis given
within 6 h of symptom onset of acute ischaemic stroke
[3-8]. Unfortunately these results do not directly apply
to patients with an acute BAO because only few, if any,
of these patients were included in randomised acute
stroke trials. As yet, BAO has not been studied in isola-
tion in randomised clinical trials. Patients with BAO
only represent about 5% of all thrombolysed stroke pa-
tients [9,10]. We are aware of only one attempt to per-
form a randomised treatment trial in patients with an
acute BAO, which was terminated prematurely because
of poor recruitment [11]. Case series of patients with
BAO found similar outcomes in patients treated with
antithrombotic therapy, intravenous thrombolysis (IVT)
or intra-arterial treatment (IAT) [11,12].
Recently our study group reported the results of the BA-
SICS registry, a prospective registry of patients with an
acute BAO [2]. We were not able to identify a statistically
significant superior treatment strategy. However the inclu-
sion of >600 patients in the registry over a 5-year period
suggests that the performance of a randomised trial in
patients with BAO is feasible.
Our observations in the BASICS registry underscore
that we continue to lack a proven treatment modality
for patients with an acute BAO and that current clinical
practice varies widely. Furthermore, the often-held
assumption that IAT is superior to IVT in patients with
an acute symptomatic BAO is challenged by our data.
Although recanalisation rates are consistently higher
after IAT as compared to IVT in observational studies,
this was not consistently accompanied by improved out-
come [13,14].
The BASICS registry was observational and has all
the limitations of a non-randomised study. Reasons
for clinicians to select a specific treatment option are
more complex than can be captured in the scope of a
prospective registry. Multivariable analyses can never
adjust completely for systematic differences between
treatment groups. A bias towards a more aggressive
treatment approach in patients who were thought tohave a worse prognosis may have influenced the out-
come in the IAT group and relinquishing both IVT
and IAT in patients with a severe deficit may have
been an expression of a more palliative approach.
Crossover to another treatment group because of clin-
ical worsening or lack of treatment response was not
taken into account. There may have been unmeasured
variables relevant to outcome that were imbalanced
between groups.
As the IAT approach becomes increasingly available
and frequently utilized an adequately powered large
randomised controlled phase III trial investigating the
added value of this therapy in patients with an acute
symptomatic BAO is needed.
Methods
BASICS is a multicentre, open label, randomised,
controlled, phase III trial comparing optimal medical
care with best intra-arterial therapy in patients with
BAO who were treated with intravenous thromboly-
sis. A total of 750 patients will be included. Follow-
up will continue until 1 year after inclusion of the
last patient.
Enrollment criteria
Patients can be enrolled in the study if the following
criteria have been met:
1. symptoms and signs compatible with ischaemia in
the basilar artery territory and an National Institutes
of Health Stroke Scale (NIHSS) ≥10 at time of
randomisation;
2. BAO confirmed by CTA or MRA;
3. aged 18 to 85 years;
4. initiation of IV rt-PA within 4.5 h of estimated time
of BAO. Estimated time of BAO is defined as time
of onset of acute symptoms consistent with the
clinical diagnosis of basilar artery occlusion or if not
known last time patient was seen normal prior to
onset of these symptoms, hence time from symptom
onset can be considerably longer than 4.5 h;
5. initiation of IA therapy should be feasible within 6 h
of estimated time of BAO;
6. informed consent.
Patients will be excluded from the study in case of:
1. pre-existing dependency with a modified Rankin
scale (mRS) ≥3;
2. female of childbearing potential who is known to be
pregnant or lactating or who has a positive
pregnancy test on admission;
3. need for haemodialysis or peritoneal dialysis;
4. other serious, advanced or terminal illness;
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pose a significant hazard to the patient if IA therapy
is initiated;
6. current participation in another research drug
treatment protocol (patient cannot start another
experimental agent until after 90 days);
7. lesion consistent with haemorrhage of any degree on
neuroimaging;
8. significant cerebellar mass effect or acute
hydrocephalus on neuroimaging;
9. bilateral extended brainstem ischaemia on
neuroimaging.
Study procedures
Based on the experience in the BASICS registry an esti-
mated 40% to 50% of patients will present in community
hospitals with subsequent referral to an intervention
centre. Community hospitals should be encouraged to
initiate IVT prior to transfer according to the ‘drip and
ship’ principle. Intubation prior to transfer should be
strongly encouraged in any subject deemed unstable or
at high risk of aspiration. If sedation is needed, short
acting drugs, like propofol (di-isopropylfenol) should
be given to avoid interference with the neurological
examination upon arrival at the intervention centre.
A diagnostic neuroimaging screening with CT/CTA
or MRI/MRA confirming the presence of BAO and the
absence of imaging exclusion criteria, and a NIHSS of
10 or more will be used to identify patients eligible
for the trial.
In case of an increase in NIHSS by ≥5 points during
transfer and in any comatose subject a repeat CT scan of
the brain should be performed prior to randomisation to
exclude intracranial hemorrhage. In those patients in
whom BAO is assessed prior to transfer a repeat CTA
should be performed prior to randomisation in the inter-
vention centre to reassess basilar artery patency in case
of an improvement in NIHSS by ≥5 points during trans-
fer or a time delay beyond 2 h after initial confirmation
of BAO and in any comatose subject.
Randomisation
After obtaining informed consent patients will be
randomised into one of the two treatment arms. Patients
are randomised by a secure link to a central randomisa-
tion database. Randomisation will be stratified for stroke
severity (NIHSS score <20 versus ≥20), for centre and
for time of symptom onset (within 4.5 h of symptom
onset versus beyond 4.5 h of symptom onset, but within
4.5 h of estimated time of BAO).
Registry of patients with BAO who are not randomised
To evaluate a possible selection bias of patients included
in the trial, participating centres are obliged to enter allpatients with acute symptomatic BAO presenting at
their centre who are treated with IVT or IAT but who
are not randomised, in a registry. Data are collected on
patient characteristics, time to treatment, eligibility, rea-
son for non-inclusion and type of treatment.
Treatment
One of the guiding principles of the BASICS trial is
rapid initiation of thrombolytic therapy to an eligible
subject to provide maximal benefit. To minimize any
delay in the administration of a proven effective therapy
(that is, IV rt-PA), the standard dose of open-label IV
rt-PA (0.9 mg/kg; 90 mg maximum) is initiated prior
to enrolment and randomisation in the trial if stand-
ard eligibility criteria are met.
Patients treated with IVT within 4.5 h of first symp-
tom onset, and those who are treated beyond 4.5 h of
first symptom onset, but within 4.5 h of estimated time
of BAO, will be regarded as two pre-specified subgroups
for secondary analysis. In patients treated beyond 4.5 h
of symptom onset, informed consent needs to be
obtained prior to initiation of IVT.
IA therapy has to be initiated within 6 h of estimated
time of BAO. Endovascular treatment will be performed
by an experienced interventional radiologist with a track
record of at least 10 intra-arterial interventions both in
the middle cerebral and basilar artery in the last 2 years.
If an appropriate thrombus or residual stenosis is identi-
fied, the choice of IA strategy will be made by the
treating neurointerventionalist.
Objectives
The primary objective of the trial is to evaluate the effi-
cacy of additional IAT in patients with BAO treated with
IVT, in terms of favourable outcome at 90 days, defined
as a modified Rankin score of 0–3.
Secondary analysis will compare outcome in the fol-
lowing pre-defined subgroups: patients with a baseline
NIHSS of 10–19, and those with a baseline NIHSS of
≥20.
Patients treated with IVT within 4.5 h of first symp-
tom onset, and those treated beyond 4.5 h of first symp-
tom onset within 4.5 h of estimated time of BAO.
Secondary objectives are safety evaluation of a com-
bined IV/IA approach compared with IV rt-PA alone,
evaluation of the safety and efficacy of mechanical
devices as part of a combined IV/IA approach and
evaluation of efficacy of a combined IV/IA approach
compared with IV rt-PA alone in terms of a favourable
outcome on other clinical and radiological measures.
Other clinical and radiological measures for evaluation
of efficacy will be: (1) Excellent outcome defined as a
mRS of 0–2 at day 90 and 1 year; (2) mRS - not dichoto-
mized at day 90 and 1 year; (3) EQ-5D at day 90 and 1
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determined by a reduction in NIHSS by 5 points or
more at 24 h; (5) a CT or MR angiography assessment
of basilar artery patency at 24 h, and (6) the extent of
cerebral infarction as measured by the pc-ASPECTS
score on NCCT (non-contrast CT) or MRI at 24 h. The
primary measures for evaluation of safety will be symp-
tomatic intracranial haemorrhage or intracranial haem-
orrhage contributing to patients’ death as determined by
the study safety committee confirmed on neuroimaging
within 3 days of treatment initiation (CT or MRI), or
overall mortality at 90 days.
Follow-up
Length of follow-up will be 1 year with a blinded exam
at day 90 (mRS, EQ-5D) and telephone surveys at 30
days (mRS) and 1 year (mRS, EQ-5D).
Statistical considerations
Power calculation
Assuming an absolute increase of 10% of favourable
outcome at 90 days by additional IA therapy compared
to optimal medical care alone, we calculated that 712
patients would be needed. This calculation was based on
a type 1 error of 5%, a type 2 error of 20%, and a pre-
sumed incidence of the primary outcome event of 30%
in the group treated with optimal medical care. This
latter incidence was based on data of the BASICS regis-
try study [2]. Based on these assumptions the trial would
yield a risk ratio of 1.33 with a 95% confidence interval
of 1.09 to 1.63, that is, a relative increase of 33% more
patients with a favourable outcome with additional IA
therapy. The sample size formula used originated from
the standard work on clinical trials by SJ Pocock [15].
To account for potential dropout a target of 750 patients
was set.
Data analysis
Continuous data will be summarised with means and
standard deviations. For count data percentages will be
given.
The primary aim of the univariable analysis is to
compare the proportion of patients with a favourable
outcome at 90 days between the two treatment
groups. For this purpose a risk ratio with corresponding
95% CI will be calculated. The analyses will be based on
the intention-to-treat principle.
Multivariable analyses will only be carried out if
important incomparability is detected between the
two treatment groups. In that case risk ratios will be
calculated that are adjusted for the variables that
show baseline imbalance. To this end Poisson regres-
sion will be used, similar to that used in the BASICS
registry study [2].Safety reporting
An adverse event (AE) is any unfavourable and unin-
tended sign, symptom, or disease occurring during the
follow-up period of the study. Adverse events occurring
after randomisation will be recorded on the adverse
event page of the CRF. A serious adverse event (SAE) is
defined as any adverse event that results in: (1) death;
(2) a life-threatening condition; (3) inpatient hospitalisa-
tion or prolongation of existing hospitalisation; or (4)
persistent or significant disability/incapacity.
Adverse reactions are all untoward and unintended re-
sponses to the investigational treatment related to any
dose or device used.
Serious unexpected adverse reactions (SUSARs) are
adverse reactions, of which the nature, or severity, is not
consistent with the applicable product information.
All SAEs and SUSARS will be reported to and col-
lected by the data coordination unit. An Internal
Safety Committee will review safety data on an on-
going basis, including monitoring the trend in serious
adverse outcome events and submitting reports to
regulatory agencies and the data safety monitoring
board (DSMB).
Monitoring
An independent DSMB will monitor the trial. For effi-
cacy a symmetrical two-sided stopping rule will be used.
The size of the trial is based on the assumption of a 10%
absolute increase of the proportion of patients with a
favourable outcome treated with additional IA therapy
as compared with optimal medical care alone. If the ob-
served benefit is ‘clearly’ larger or if optimal medical care
appears to be better than additional IA therapy early ter-
mination of the trial may be recommended. A restricted
procedure will be used with alpha equal to 0.05 and a
power of 0.80 [16].
Safety will be monitored as follows. The BASICS regis-
try observed that the risk of symptomatic intracranial
haemorrhage (sICH) in patients treated with IA therapy
was 14% (95% CI 10-18%) and 7% (95%CI 3-11%) in
those treated with IVT only [2]. A more than two-fold
excess of symptomatic intracranial haemorrhage in the
group treated with additional IA therapy as compared
with maximum supportive treatment may therefore be
considered as problematic. However, symptomatic intra-
cranial haemorrhage is a contributing component of the
primary outcome and hence is weighed during monitor-
ing of this outcome. A higher than expected sICH rate
in the absence of a significant difference in functional
outcome may therefore lead to a decision to put the trial
on hold to analyse the reason for this higher sICH rate
and the need to change treatment recommendations
such a adjustments in the dose of thrombolytics used or
the use of specific devises.
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system into effect, such that for each patient 90-day
follow-up data and those on the occurrence of symp-
tomatic intracranial haemorrhage are obtained without
delay. The first interim analysis will be performed at the
moment the 3-month follow-up data are available on the
first 10 patients randomised. Every 4 months thereafter
the DSMB will be given the latest follow-up data and
will advise the steering committee about the continu-
ation of the trial based on these data. Thus a sequential
monitoring process is installed based on the procedures
described by Whitehead in 1997 [16]. For this purpose
the program PEST 4 will be used. The recommendation
on the continuation will be based on: (1) stopping rules
as described above; and (2) the most recent information
from medical literature or congresses in the field of cere-
brovascular disease.
Ethical considerations
The study will be conducted according to the principles of
the Declaration of Helsinki (www.wma.net21-10-2008)
and in accordance with the Dutch Medical Research In-
volving Human Subjects Act (WMO). The BASICS trial
was approved by the ethics committee of the St. Antonius
Hospital on 20 January 2011 and is registered under num-
ber R-10.39A. National ethical approval was given by the
Central Commission of Human Research (CCMO) on
21 December 2010 and is registered under number
NL33550.100.10. Approval by the local medical ethical re-
view board is required for each participating centre before
start of patient inclusion.
Patients or their legal representatives will be informed
about the trial by their treating neurologist or neurology
resident who will also obtain informed consent. In acute
situations or if the patient is incapable to give written
informed consent oral informed consent may be
obtained. In case of oral informed consent a witness (for
example, family or nurse) should be present when the
information is presented to the patient or patient repre-
sentative. A written summary that describes the essential
information will be presented to the patient or patient
representative. The witness, and responsible neurologist
or neurology resident will sign this document.
In case of a subject with severe decrease of conscious-
ness (along with national legislations), informed consent
can be obtained from the patient’s proxy in person or by
telephone as long as the identity of the proxy can be
confirmed. If approved by the local ethical review board
an independent physician can sign informed consent.
Community hospitals are encouraged to obtain informed
preliminary consent for trial participation of the subject
or his proxy prior to transfer.
In patients who are not eligible for standard IVT be-
cause IVT cannot be initiated within 4.5 h of symptomonset but who are treated within 4.5 h of estimated time
of BAO informed consent has to be obtained prior to
IVT. In those centres where CTA or MRA is not part of
the standard acute stroke work-up informed consent has
to be obtained prior to CTA or MRA.
Publication of the trial results
The trial results will be published by the members of
the Executive and Steering Committee, on behalf of the
investigators.
Discussion
There are several factors that distinguish patients
with BAO from those with middle cerebral artery
(MCA) occlusion that may warrant a different treat-
ment approach:
Severity of deficit: previous studies have suggested a
greater benefit of IA therapy in patients with a severe
deficit.
High poor outcome rate: because of a higher poor out-
come rate, patients with BAO have more to gain.
Collateral flow: the basilar artery not only receives col-
lateral flow through cortical cerebellar branches, compar-
able to the cortical hemispheric branches of the MCA, but
also by retrograde filling by the anterior circulation through
the posterior communicating arteries as part of the circle of
Willis. IVT may be more effective in the presence of good
collateral flow, by attacking the thrombus from both sides.
Time window for treatment: the BASICS registry data
suggest the presence of a longer time window from
symptom onset to time of treatment. The PROACT
studies used a limit of time from symptom onset to time
of treatment of 6 h [4,17]. The IMS III study used a 5-h
time window from symptom onset to initiation of IAT
[18]. The BASICS trial uses a 6-h time window from
estimated time of BAO to initiation of IA treatment.
The BASICS registry used the estimated time of symptom
onset consistent with the clinical diagnosis of BAO to
treatment rather than the more commonly used time of
onset of any symptoms to treatment. Previous studies
have shown that BAO is preceded by prodromal symp-
toms in >60% of patients [19,20]. Most of these patients
would be excluded from a potential trial using the time of
onset of first symptom <4.5 h to treatment as an inclusion
criterion. We believe that the results from the BASICS
registry support the use of the estimated time of BAO ra-
ther than using the time of onset of any symptom to treat-
ment as an inclusion criterion for the BASICS trial.
IVT versus IVT/IAT comparison: IV thrombolysis is
the current standard of care in patients presenting with
acute ischaemic stroke with a proven safety and efficacy
and therefore should be regarded as the current ‘Gold
Standard’ with which potential new treatment strategies
should be compared.
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acute symptomatic BAO is supported by the results of
the BASICS registry in which no significant difference
was found between IVT or IAT treated patients with a
severe deficit [2].
The performance of a trial comparing IVT alone vs. IAT
alone in patients with BAO does not seem feasible nor
ethical. Referral of a patient to an intervention centre for
randomisation between IVT vs. IAT alone would mean
delaying the initiation of a treatment which is of proven
benefit - whereas there is convincing evidence for the
principle of ‘time is brain’, also in patients with BAO
[21,22]. The number of patients with BAO presenting
directly to an intervention centre will be too limited.
Patients with BAO only represent an approximate 5% of
all IVT eligible patients, and only 40% of patients in the
BASICS registry where admitted directly (without referral)
to an intervention centre.
In order to include a sufficient number of patients the
BASICS trial will therefore mainly depend on the inclusion
of patients referred from non-intervention community
hospitals. The non-intervention hospitals are encouraged
to start IVT without delay before sending the patient with
the clinical diagnosis of BAO to the intervention centre.
A combined IV and IA approach to acute ischaemic
stroke therapy was designed to offer rapid initiation of
IV rt-PA, followed by additional titrated local IA therapy,
to patients with moderate-to-severe strokes (NIHSS ≥10).
The goal was to achieve higher rates of early, successful
reperfusion in a widely accessible manner. This approach
has been tested in clinical trials of >200 patients, starting
with the Emergency Management of Stroke (EMS) pilot
trial from 1995 to 1996, followed by the Interventional
Management of Stroke (IMS) I trial in 2001, the IMS II
trial from 2003 to 2006, and several additional cohorts
[23-25]. The data from EMS and IMS show that the com-
bined approach to recanalisation may be more effective
than standard IV rt-PA alone for moderate-to-severe
(NIHSS ≥10) strokes, while maintaining a similar safety
profile. The recently published IMS III trial data did not
show a significant difference in outcome comparing
IV rt-PA with IV rt-PA followed by IAT in patients
with a NIHSS of 8 or greater treated within 3 h [26].
Few patients with BAO were included, about 2% in
both treatment arms. Furthermore, few patients had
radiologic confirmation of occlusion and most patients in
the IA arm were treated with IA thrombolysis or first gen-
eration thrombectomy devices, much less effective than
the currently used stentretrievers [27,28].
IVT arm
The 4.5-h time window is based on the results of the
ECASS III study [7]. A time window of 0–4.5 h from
symptom onset to treatment in patients with acuteischaemic stroke is widely accepted. The BASICS regis-
try results show the safety of using a 0 to 4.5-h time
window from estimated time of occlusion to treatment
in patients with acute BAO [2].
IVT + IAT arm
Based on the results of the PROACT studies the 6-h
time window for IA thrombolysis in patients with MCA
occlusion is widely accepted [4,17].
A case series of 69 patients treated with IA thromboly-
sis (urokinase, reteplase or alteplase) following full dose
IVT showed the safety of full dose IVT followed by IA
thrombolysis. Symptomatic haemorrhage occurred in
four out of 69 (5.8%) patients [29].
The MERCI studies suggested safety of mechanical
thrombectomy up to 8 h from symptom onset [30]. The
BASICS study shows that a time window of 0 to 6 h
from estimated time of occlusion to IA treatment is safe
in patients with a severe deficit while little can be gained
in both IVT and IAT treated patients beyond the 6-h
time window [2].
The main theoretical advantage of an IA approach is
the variety of treatment options, which can be tailored
to the individual patient. Because of the variety in ap-
proved IA treatment options and the limited number of
patients, the experience with specific devices or throm-
bolytics varies considerably among stroke centres both
within and between countries. Limiting the use of treat-
ment options would exclude centres from participation
because of lack of experience with the selected device or
thrombolytic despite ample experience in the use of
alternative devices or thrombolytics. New devices or
thrombolytics that become available during the study
may be used in the IAT arm depending on national and
local approval and experience. Prior approval by the
steering committee needs to be obtained.
Trial organisation
Steering committee
The Steering Committee carries the ultimate responsibil-
ity for the trial. Specific tasks of the steering Committee
are: (1) approval of the study protocol; (2) approval of
amendments to the study protocol; (3) deciding whether
or not to continue the trial based on the recommenda-
tion of the DMSB; (4) reviewing protocols for satellite
studies; and (5) approval of reports and publication of
the trial.
As of 18-10-2012, members of the Steering Committee
are (in alphabetical order):
A. Algra*, clinical epidemiologist, University Medical
Center Utrecht, Utrecht, the Netherlands;- H.J.
Audebert*, neurologist, Charité Berlin, Berlin, Germany;
E. Berge, neurologist, Oslo University Hospital Ullevål,
Oslo, Norway; A. Ciccone, neurologist, Carlo Poma
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versity Medical Center Utrecht, Utrecht, the Netherlands;
M. Mazighi, interventional neurologist, Bichat University
Hospital, Paris, France; P. Michel*, neurologist, University
Medical Centre Vaudois, Lausanne, Switzerland; K.W.
Muir, neurologist, University Medical Centre Glasgow,
Glasgow, United Kingdom; V. Obach, neurologist, Clinic
Hospital Barcelona, Barcelona, Spain; V. Puetz, neur-
ologist, Dresden Stroke Centre, Dresden, Germany;
W.J. Schonewille*, neurologist, St. Antonius Hospital,
Nieuwegein, the Netherlands, principal investigator; J.A.
Vos*, interventional radiologist, St. Antonius Hospital,
Nieuwegein, the Netherlands, co-principal investigator;
C.A.C. Wijman†, neurologist, Stanford University Medical
Centre, Palo Alto, CA, USA; A. Zini, neurologist, St.
Agostino-Estense Hospital, Modena, Italy.
* Also member of the Executive Committee
† Deceased
Executive Committee
As of 18 October 2012, members of the Executive Com-
mittee, who are responsible for the trial on a day-to-day
basis, are all members of the Steering Committee indicated
with an * and E.J.R.J. van der Hoeven, radiology
resident, St. Antonius Hospital, Nieuwegein, the
Netherlands, coordinating investigator.
Trial Coordination Centre
The Trial Coordination Centre is located at the Neurology
department in the St. Antonius Hospital Nieuwegein in
the Netherlands.
Data Safety and Monitoring Board
An independent Data Safety and Monitoring Board,
consisting of clinicians familiar with the treatment of
stroke, a biostatistician and a neuro-interventionalist,
has been established to monitor the progress of the trial.
Details on the advice(s) of the DSMB will be notified to
the Steering Committee and the METC that approved
the protocol. With this notification a statement will be
included indicating whether the advice will be followed.
As of 15 April 2011, members of the Data Safety and
Monitoring Board, are (in alphabetical order): K.T.
Hoffmann, interventional radiologist, University of
Leipzig, Leipzig, Germany; P. Lyden, neurologist,
Cedars-Sinai MC, Los Angeles, CA, USA (Chair); R.
Raman, Biostatistician, University California, San Diego,
CA, USA; D. Toni, neurologist, University ‘La Sapienza’,
Rome, Italy.
Trial status
The trial started in October 2011 in the coordinating
centre, the St Antonius Hospital Nieuwegein with the
inclusion of the first patient. Eleven other centres in theNetherlands, Switzerland, Czech Republic and Italy have
joined since then. As of July 2013 21 patients have been
randomised. In Germany, France and Spain the protocol
is awaiting national ethical approval. Several other
Dutch, German, French, Czech, Swiss, Italian, Spanish
and Norwegian centres have indicated that they are
interested in participating (www.basicstrial.com).
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